Status:
UNKNOWN
Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer
Lead Sponsor:
Blood Transfusion Centre of Slovenia
Collaborating Sponsors:
University Medical Centre Ljubljana
Conditions:
Pancreatic Tubular Adenocarcinoma
Eligibility:
All Genders
30-85 years
Brief Summary
Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.
Eligibility Criteria
Inclusion
- ECOG performance status 0-2 at the time of inclusion
- Following R0 or R1 pancreatic tubular adenocarcinoma resection
Exclusion
- Pregnancy
- Serious comorbidity
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
End Date :
December 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00947102
Start Date
February 1 2009
End Date
December 1 2011
Last Update
January 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre Ljubljana; Department for Gastroenterology
Ljubljana, Ljubljana, Slovenia, 1000